Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 6;14(1):42.
doi: 10.1186/s40545-021-00319-6.

Cardiovascular disease risk prevention services by pharmacists in Saudi Arabia: what do policymakers and opinion leaders think?

Affiliations

Cardiovascular disease risk prevention services by pharmacists in Saudi Arabia: what do policymakers and opinion leaders think?

Hadi A Almansour et al. J Pharm Policy Pract. .

Abstract

Background: Cardiovascular disease (CVD) is an emerging contributor to national morbidity and mortality in Saudi Arabia. CVD risk prevention services are limited, particularly with an over-utilised public health sector and an under-utilised and under-resourced primary care sector. Globally, there is evidence that community pharmacists can play a key role in CVD prevention within primary care. However, the perspectives of policymakers and opinion leaders are critical to successful translation of evidence into practice. Thus, the aim was to engage policymakers and professional leaders in discussions about implementing high-quality CVD risk prevention services in community pharmacy.

Methods: Qualitative semi-structured interviews were conducted, audio-recorded and transcribed verbatim. All transcripts were thematically analysed.

Results: A total of 23 participants (87% male) from government and non-government sectors were interviewed. Of these, almost 65% had pharmacy qualifications. Limited provision of CVD risks preventative services in primary care was acknowledged by most participants and building community pharmacists' capacity to assist in preventive health services was viewed favourably as one way of improving the status quo. The data yielded four key themes: (1) future pharmacy CVD health service models; (2) demonstrable outcomes; (3) professional engagement and advocacy; and (4) implementability. CVD health services roles (health screening, primary and secondary prevention services), pragmatic factors and tiered models of care (minimal, medium, and comprehensive pharmacist involvement) were discussed. The need for humanistic, clinical, and cost effectiveness outcomes to be demonstrated and active involvement of professional bodies were deemed important for such services to be sustainable. Professional pharmacy governance to develop pharmacy careers and workforce, pharmacy curricular reform and ongoing education were posed as key success factors for novel pharmacy roles. Practice policies, standards, and guidelines were seen as required to adhere to stringent quality control for future pharmacy services provision. Participant's implementation vision for such services included scalability, affordability, access, adoption and health system reform. Most discussions focused on the need for structural improvement with limited input regarding processes or outcomes required to establish such models.

Conclusions: Most participants favoured pharmacy-based CVD risk prevention services, despite the variability in proposed service models. However, prior to developing such services, support structures at the health system and health professional level are needed as well as building public support and acceptability for pharmacy services.

Keywords: CVD risk prevention services; Pharmacists; Pharmacy services; Policymakers; System reform.

PubMed Disclaimer

Conflict of interest statement

The authors report no competing interest.

Figures

Fig. 1
Fig. 1
Perceived CVD risk prevention service models of care
Fig. 2
Fig. 2
Potential Saudi pharmacy CVD risk prevention/management service—service elements that would need to be in place prior to implementation
Fig. 3
Fig. 3
Implementation steps suggested

Similar articles

Cited by

References

    1. Nagaria RA, Hasan SS. Pharmacy, pharmaceuticals and public policy: Solving the puzzle. Res Soc Adm Pharm. 2020;16:840–843. doi: 10.1016/j.sapharm.2019.07.010. - DOI - PubMed
    1. Hermansyah A, Sainsbury E, Krass I. Multiple policy approaches in improving community pharmacy practice: the case in Indonesia. BMC Health Serv Res. 2018;18(1):449. doi: 10.1186/s12913-018-3258-8. - DOI - PMC - PubMed
    1. Kruk ME, Freedman LP. Assessing health system performance in developing countries: a review of the literature. Health Policy. 2008;85(3):263–276. doi: 10.1016/j.healthpol.2007.09.003. - DOI - PubMed
    1. Schoemaker CG, van Loon J, Achterberg PW, den Hertog FR, Hilderink H, Melse J, et al. Four normative perspectives on public health policy-making and their preferences for bodies of evidence. Health Res Policy Syst. 2020;18(1):1–7. doi: 10.1186/s12961-020-00614-9. - DOI - PMC - PubMed
    1. Buss VH, Shield A, Kosari S, Naunton M. The impact of clinical services provided by community pharmacies on the Australian healthcare system: a review of the literature. J Pharm Policy Pract. 2018;11(1):22. doi: 10.1186/s40545-018-0149-7. - DOI

LinkOut - more resources